If you invested $1,000 in ResMed (ASX:RMD) shares a decade ago, here's what they would be worth now

Was it better to invest in ResMed shares or the ASX 200 over the past decade?

The ResMed Inc (ASX: RMD) share price has enjoyed strong returns over the past 10 years, up 1,300%. In comparison, the S&P/ASX 200 Index (ASX: XJO) is up around 80% over the same time frame.

Below, we take a look at the power of long-term investing. Let's calculate how much you would have made if you invested $1,000 in ResMed shares a decade ago.

two hands wearing medical gloves make the shape of a heart, indicating the best healthcare shares on the ASX market

Image source: Getty Images

How does ResMed compare against the ASX 200?

On average, the ASX 200 has returned a yearly average of 5.84% to shareholders in the past decade. The most significant gain was achieved in 2019 when the index grew by 23.02%.

On the other hand, the biggest fall came in 2011, down by 10.84%. You might be thinking that 2020 would be on the list due to major COVID-19 disruptions, but the ASX 200 rebounded sharply during that year.

The healthcare company's shares have historically outperformed the ASX 200 by a long shot, consistently treading upwards. In the past 10 years, the company has delivered a yearly average return of 30.34% since 2011.

What if you had invested $1,000 in ResMed shares 10 years ago?

If you had invested $1,000 in ResMed shares on this day 10 years ago, you would have bought them for around $2.78 each. This would have given you approximately 359 shares without factoring in any dividend reinvestments over the years.

Fast-forward to today, the current ResMed share price at the time of writing is $39.43. This means those 359 shares would now be worth an astonishing $14,155.37 (359 shares x $39.43). When considering percentage terms, this implies an upside of 1,315%.

Are ResMed shares a buy now?

Following the company's full-year results, a number of brokers rated ResMed shares with similar price points.

Last month, Goldman Sachs raised its 12-month price target by 27% to $36.20 for the healthcare company's shares. Macquarie soon followed, adding 7.3% to its outlook of $37.40 per share.

The most recent note came from Citi, which lifted its price on ResMed shares by 12% to $36.50.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Could Telix Pharmaceuticals shares double in value over the next 12 months?

Find out if the ASX biotech stock is a buy, sell, or hold now.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 compelling reasons to consider buying Mesoblast shares

This company has a lot going on, plus strong revenues.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Are CSL shares a buy, hold, or sell at their 52-week high?

Investors have become much more optimistic about its future. But has the share price recovery gone too far?

Read more »

Senior man looking at his laptop and pondering something.
Healthcare Shares

Would I buy ResMed shares after today's results?

The company has reported solid revenue and earnings growth. Here's what I make of its performance and current valuation.

Read more »